Akèy › Kolit Ulseratif › Lwizyàn
Etid klinik pou Kolit Ulseratif nan Lwizyàn
15 etid pou Kolit Ulseratif ap chèche patisipan nan sit nan Lwizyàn.
Vil nan Lwizyàn
Tèks ofisyèl etid la (Anglè)
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastro Group and Endocenter: Mandeville, la /ID# 284186, Mandeville
- Metropolitan Gastroenterology Associates - Metairie /ID# 283922, Metairie
- Willis-Knighton Medical Center /ID# 280572, Shreveport
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Oct 1, 2026 · NCT07697456A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Baton Rouge General Medical Center - Bluebonnet Campus, Baton Rouge
- Combined Gastro LLC, Lafayette
- GI Alliance, Metairie
Ap rekriteFaz 4
Laj 18 a 80 · Tout sèks · Mizajou Sep 30, 2026 · NCT06581328A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
- Clinical Trials Management, LLC, Metairie
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 30, 2026 · NCT06598943A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis
- Site 035, Marrero
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT07012395A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
- Site US-008, Baton Rouge
- Site US-011, Mandeville
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 29, 2026 · NCT07845487A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)
- Tulane University School of Medicine-Gastroenterology and Hepatology ( Site 1073), New Orleans
Ap rekriteFaz 2
Laj 18 a 75 · Tout sèks · Mizajou Sep 28, 2026 · NCT07463183A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
- Delta Research Partners, LLC, West Monroe
Ap rekriteFaz 3
Laj 12 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT07196748Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Care Access - New Iberia, New Iberia
- Louisiana Research Center, Shreveport
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 24, 2026 · NCT06937086LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
- GI Alliance - Gastro Group and Endocenter - Mandeville, Mandeville
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Sep 22, 2026 · NCT07415044A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)
- GI Alliance, Metairie
- Tulane University, New Orleans
Ap rekriteFaz 4
Laj 18 a 65 · Tout sèks · Mizajou Sep 21, 2026 · NCT06095128A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- GI Alliance - Baton Rouge - Site Number: 8400129, Baton Rouge
- Texas Digestive Disease Consultants, PLLC d/b/a GI Alliance - Mandeville - Site Number: 8400128, Mandeville
- Delta Research Partners - Site Number: 8400087, Monroe
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Sep 15, 2026 · NCT07185009A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis
- Gastroenterology Clinic of Acadiana, Lafayette
Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Aug 28, 2026 · NCT07577856An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
- GI Alliance - Baton Rouge - Site Number: 8400129, Baton Rouge
- Tandem Intermediate, LLC - Houma -Site Number: 8400034, Houma
- GastroGroup - Site Number: 8400128, Mandeville
- ak 4 plis
Ap rekriteFaz 3
Laj 16 a 80 · Tout sèks · Mizajou Aug 20, 2026 · NCT07184996A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
- Mirador Therapeutics Selected Site, Lafayette
- Mirador Therapeutics Selected Site, Marrero
- Mirador Therapeutics Selected Site, Shreveport
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Mar 12, 2026 · NCT07113522Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention
- Tulane University, New Orleans
Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou May 8, 2025 · NCT06750731Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.